Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study

被引：8
作者：
Rossi, E
Perrone, F
Labonia, V
Landi, G
Nuzzo, F
Amabile, G
Gridelli, C
Di Maio, M
D'Aiuto, G
de Matteis, A
机构：
[1] Natl Canc Inst, Div Med Oncol C, I-80131 Naples, Italy
[2] Natl Canc Inst, Clin Trials Unit, I-80131 Naples, Italy
[3] Civil Hosp, Monteforte, Italy
来源：
ONCOLOGY | 2003年 / 64卷 / 04期
关键词：
D O I：
10.1159/000070313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：479 / 480
页数：2
相关论文
共 6 条
  • [1] In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents
    Budman, DR
    Calabro, A
    Kreis, W
    [J]. ANTI-CANCER DRUGS, 1998, 9 (08) : 697 - 702
  • [2] ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE
    CARMICHAEL, J
    POSSINGER, K
    PHILLIP, P
    BEYKIRCH, M
    KERR, H
    WALLING, J
    HARRIS, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2731 - 2736
  • [3] VINORELBINE IS AN ACTIVE ANTIPROLIFERATIVE AGENT IN PRETREATED ADVANCED BREAST-CANCER PATIENTS - A PHASE-II STUDY
    GASPARINI, G
    CAFFO, O
    BARNI, S
    FRONTINI, L
    TESTOLIN, A
    GUGLIELMI, RB
    AMBROSINI, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) : 2094 - 2101
  • [4] Gemcitabine plus vinorelbine in advanced non small cell lung cancer: a phase II study of three different doses
    Gridelli, C
    Frontini, L
    Perrone, F
    Gallo, C
    Gulisano, M
    Cigolari, S
    Castiglione, F
    Robbiati, SF
    Gasparini, G
    Ianniello, GP
    Farris, A
    Locatelli, MC
    Felletti, R
    Piazza, E
    [J]. BRITISH JOURNAL OF CANCER, 2000, 83 (06) : 707 - 714
  • [5] Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor
    Haider, K
    Kornek, GV
    Kwasny, W
    Weinländer, G
    Valencak, J
    Lang, F
    Püribauer, F
    Kovats, E
    Depisch, D
    Scheithauer, W
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1999, 55 (03) : 203 - 211
  • [6] Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
1